Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Rudloff Website

Udo Rudloff, M.D., Ph.D.

Selected Publications

1)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer.
Hum. Gene Ther. [Epub ahead of print], 2014.
2)  Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial.
Ann. Surg. Oncol. [Epub ahead of print], 2014.
3)  Lau C, Killian KJ, Samuels Y, Rudloff U.
ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Methods Mol. Biol. 1102: 461-80, 2014.
4)  Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I.
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial.
J Surg Oncol. 110: 275-84, 2014.
5)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
6)  Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, Collins I, Zhou W, Wang Z, Powell J, Thorgeirsson SS, Rudloff U, Petersen GM, Amundadottir LT.
An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer.
BMC Med Genomics. 6: 33, 2013.
7)  Langan RC, Gill F, Raiji MT, Mullinax JE, Pittaluga S, Pandalai P, Davis J, Perkins K, Avital I, Rudloff U.
Autoimmune pancreatitis in the autoimmune lymphoproliferative syndrome (ALPS): a sheep in wolves' clothing?.
Pancreas. 42: 363-6, 2013.
8)  Xin H, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen J, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Gut. 62: 1777-86, 2013.
9)  Langan RC, Sherry RM, Avital I, Heller T, Henderson C, Holland SM, Freeman AF, Rudloff U.
Safety of Major Abdominal Surgical Procedures in Patients with Hyperimmunoglobulinemia E (Job"s Syndrome): a Changing Paradigm?.
J. Gastrointest. Surg. 17: 1009-14, 2013.
10)  Langan RC, Lagisetty KH, Atay S, Pandalai P, Stojadinovic A, Rudloff U, Avital I.
Surgery for Li Fraumeni Syndrome: Pushing the Limits of Surgical Oncology.
Am. J. Clin. Oncol. [Epub ahead of print], 2013.
11)  Xin HW, Ambe CM, Ray S, Kim BK, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.
Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division.
J Cancer. 4: 447-57, 2013.
12)  Langan RC, Mullinax JE, Ray S, Raiji MT, Schaub N, Xin HW, Koizumi T, Steinberg SM, Anderson A, Wiegand G, Butcher D, Anver M, Bilchik AJ, Stojadinovic A, Rudloff U, Avital I.
A Pilot Study Assessing the Potential Role of non-CD133 Colorectal Cancer Stem Cells as Biomarkers.
J Cancer. 3: 231-40, 2012.
13)  Jaiswal KR, Xin HW, Anderson A, Wiegand G, Kim B, Miller T, Hari D, Ray S, Koizumi T, Rudloff U, Thorgeirsson SS, Avital I.
Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells.
Stem Cell Res. 9: 249-60, 2012.
14)  Ray S, Langan RC, Mullinax JE, Koizumi T, Xin HW, Wiegand GW, Anderson AJ, Stojadinovic A, Thorgeirsson S, Rudloff U, Avital I.
Establishment of human ultra-low passage colorectal cancer cell lines using spheroids from fresh surgical specimens suitable for in vitro and in vivo studies.
J Cancer. 3: 196-206, 2012.
15)  Langan RC, Ripley RT, Davis JL, Prieto PA, Datrice N, Steinberg SM, Bratslavsky G, Rudloff U, Kammula US, Stojadinovic A, Avital I.
Liver directed therapy for renal cell carcinoma.
J Cancer. 3: 184-90, 2012.
16)  Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, Rudloff U, Lin JC, Rosenberg SA, López-Otín C, Samuels Y.
Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma.
Hum. Mutat. 32: E2148-75, 2011.
17)  Rudloff U, Samuels Y.
A growing family: Adding mutated Erbb4 as a novel cancer target.
Cell Cycle. 9: 1487-503, 2010.
18)  Rudloff U, Bhanot U, Gerald W, Klimstra DS, Jarnagin WR, Brennan MF, Allen PJ.
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality.
Ann. Surg. Oncol. 17: 2229-36, 2010.
19)  Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ.
Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.
J. Clin. Oncol. 28: 3762-9, 2010.
20)  Rudloff U, Maker AV, Brennan MF, Allen PJ.
Randomized clinical trials in pancreatic adenocarcinoma.
Surg. Oncol. Clin. N. Am. 19: 115-50, 2010.
21)  Rudloff U, Brogi E, Reiner AS, Goldberg JI, Brockway JP, Wynveen CA, McCormick B, Patil S, Van Zee KJ.
The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy.
Ann. Surg. 251: 583-91, 2010.
22)  Rudloff U, Samuels Y.
TYRO3-mediated regulation of MITF: a novel target in melanoma?.
Pigment Cell Melanoma Res. 23: 9-11, 2010.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/15/2014.